Clinical trial
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low…
NCT00458159 · Celgene, Industry · Terminated
Key facts
| NCT number | NCT00458159 |
|---|---|
| Title | A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes |
| Official title | A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes |
| Lead sponsor | Celgene, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | CC-11006 |
| Enrollment | 34 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Apr 9, 2007 |
| Last update posted | Dec 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: